Germany industry debates medtech aids changes:
This article was originally published in Clinica
Executive Summary
Representatives from Germany's IKK Guilds' health sickness fund (the one delegated as "rapporteur" on this issue of fixed reimbursement prices for medical technical aids - see Clinica No 1138, p 6) will be among the speakers at a BVMed/MedInform-organised forum on the theme of fixed prices, in Mainz on April 7. The session will deal with prescribing, how hospitals view and deal with the fixed prices, how are the prices calculated, and what will be the effect on patient care and medical technology companies. For details, a programme and for online or other registration information, contact BVMed in Berlin, on tel: +49 (0)30 246 25520; email: [email protected]
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.